American Kratom Association realizes FDA could have significant influence on DEA decision on whether to schedule kratom constituent ingredients as controlled substances. The association and experts on kratom say FDA's, which concluded that mitragynine and 7-hydroxymitragynine are opioids and use of kratom is dangerous, contains numerous inaccuracies and incorrect conclusions.
The clock is ticking on kratom remaining available in the US, proponents for the botanical ingredient say, unless the Drug Enforcement Administration rejects FDA's findings about its safety and chemical profile.
The American Kratom Association anticipates that FDA will have significant influence on DEA's decision on whether to schedule kratom constituent...